Agenus has signed $141m partnership agreements with Zydus Lifesciences and its subsidiaries to enhance clinical developments ...

In this issue: assessing the regulators' role as AI in clinical trials evolves, the potential for a newborn screening refresh ...

Already offering the only non-invasive treatment for SMA in liquid form, Roche’s Evrysdi now comes as a tablet.

The European Commission (EC) has granted approval for Takeda's antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin).

AbbVie’s telisotuzumab adizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this ...

First-in-human data for the trispecific antibody “suggest a paradigm shift” for the relapsed/refractory multiple myeloma ...

SpyGlass Pharma has closed a Series D funding round, raising $75m to advance the company's drug delivery platform.

The ADC market was valued at $8.6bn in 2023, with it forecast to exceed $45bn by 2030, according to analysis by GlobalData.

The FDA has granted expanded access authorisation for ImmunityBio’s Cancer BioShield platform, anchored by Anktiva, to treat ...

The FDA set a PDUFA date in late 2025 as ziftomenib led to significant disease response in patients with common subtype of ...

Bristol Myers Squibb (BMS) is joining forces with BioNTech in a deal that could surpass $11bn as the two drugmakers look to ...

Sanofi has signed an agreement to acquire US-based Blueprint Medicines to bolster its immunology pipeline with rare disease ...